Thomas Morel

Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort

Antoine Regnault, Babak Boroojerdi, Juliette Meunier et al. · Journal of Neurology · 2019 · 237 citations · Full text

Medicine, Neurology, Neuroscience +17

Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group

Sandra Nestler-Parr, D Korchagina, Mondher Toumi et al. · Value in Health · 2018 · 141 citations · Full text

Public Affairs, Health Informatics, Health Policy +9

Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries

Thomas Morel, Francis Arickx, Gustaf Befrits et al. · Orphanet Journal of Rare Diseases · 2013 · 123 citations · Full text

Public Affairs, Health Policy, Pharmaceutical Policy +14

Shining a light in the black box of orphan drug pricing

Eline Picavet, Thomas Morel, David Cassiman et al. · Orphanet Journal of Rare Diseases · 2014 · 61 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacoeconomics +17

Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers

Thomas Morel, Ségolène Aymé, David Cassiman et al. · Orphanet Journal of Rare Diseases · 2016 · 46 citations · Full text

Pharmacy, Health Sciences, Health Assessment +16